Divis Laboratories gets EIR for Unit-II at Visakhapatnam

From USFDA

Divis Laboratories has received an Establishment Inspection Report (EIR) from US-FDA for the Company's Unit-II at Visakhapatnam, as closure of audit by FDA.

The company's Unit-II at Visakhapatnam was inspected by US-FDA in September 2017 wherein a Form-483 was issued with 6 observations.

Powered by Capital Market - Live News